{"id":"azilsartan-medoxomil","rwe":[],"_fda":{"id":"2f63b0e8-977a-4d22-9550-29ad1926a9de","set_id":"52b27c75-9f5a-4816-bafd-dace9d7d2063","openfda":{"upc":["0360631080308","0360631040302"],"route":["ORAL"],"rxcui":["1091646","1091650","1091652","1091654"],"spl_id":["2f63b0e8-977a-4d22-9550-29ad1926a9de"],"brand_name":["Edarbi"],"spl_set_id":["52b27c75-9f5a-4816-bafd-dace9d7d2063"],"package_ndc":["60631-040-07","60631-040-30","60631-040-77","60631-080-07","60631-080-30","60631-080-77"],"product_ndc":["60631-040","60631-080"],"generic_name":["AZILSARTAN KAMEDOXOMIL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AZILSARTAN KAMEDOXOMIL"],"manufacturer_name":["Azurity Pharmaceuticals, Inc."],"application_number":["NDA200796"],"is_original_packager":[true]},"version":"17","pregnancy":["8.1 Pregnancy Risk Summary Edarbi can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death ( see Clinical Considerations ). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue Edarbi as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Edarbi for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to Edarbi, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function . Data Animal Data In peri- and postnatal rat development studies, adverse effects on pup viability, delayed incisor eruption and dilatation of the renal pelvis along with hydronephrosis were seen when azilsartan medoxomil was administered to pregnant and nursing rats at 1.2 times the MRHD on a mg/m 2 basis. Reproductive toxicity studies indicated that azilsartan medoxomil was not teratogenic when administered at oral doses up to 1000 mg azilsartan medoxomil/kg/day to pregnant rats (122 times the MRHD on a mg/m 2 basis) or up to 50 mg azilsartan medoxomil/kg/day to pregnant rabbits (12 times the MRHD on a mg/m 2 basis). M-II also was not teratogenic in rats or rabbits at doses up to 3000 mg M-II/kg/day. Azilsartan crossed the placenta and was found in the fetuses of pregnant rats and was excreted into the milk of lactating rats."],"overdosage":["10 OVERDOSAGE Limited data are available related to overdosage in humans. During controlled clinical trials in healthy subjects, once-daily doses up to 320 mg of Edarbi were administered for seven days and were well tolerated. In the event of an overdose, supportive therapy should be instituted as dictated by the patient's clinical status. Azilsartan is not dialyzable [see Clinical Pharmacology (12.3) ] ."],"description":["11 DESCRIPTION Edarbi (azilsartan medoxomil), a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is an angiotensin II receptor blocker. The drug substance used in the drug product formulation is the potassium salt of azilsartan medoxomil, also known by the US accepted name of azilsartan kamedoxomil and is chemically described as (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1 H -benzimidazole-7-carboxylate monopotassium salt. Its empirical formula is C 30 H 23 KN 4 O 8 and its structural formula is: Azilsartan kamedoxomil is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol. Edarbi is available for oral use as tablets. The tablets have a characteristic odor. Each Edarbi tablet contains 42.68 or 85.36 mg of azilsartan kamedoxomil, which is equivalent to containing 40 mg or 80 mg respectively, of azilsartan medoxomil and the following inactive ingredients: mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, and magnesium stearate. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Edarbi tablets are unscored and white to nearly white, debossed with \"ASL\" on one side and \"40\" or \"80\" on the other. Tablet NDC 60631-xxx-xx Bottle/30 40 mg 040-30 80 mg 080-30 Storage Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from moisture and light. Do not repackage; dispense and store in original container."],"boxed_warning":["WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Edarbi as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )"],"geriatric_use":["8.5 Geriatric Use No dose adjustment with Edarbi is necessary in elderly patients. Of the total patients in clinical studies with Edarbi, 26% were elderly (65 years of age and older); 5% were 75 years of age and older. Abnormally high serum creatinine values were more likely to be reported for patients age 75 or older. No other differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3) ] ."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Use of Edarbi is not recommended in children less than 2 years of age. It is not known whether post-natal use of azilsartan in patients less than 2 years of age, before maturation of kidney function is complete, has a long-term deleterious effect on the kidney. Juvenile Animal Studies In juvenile rat studies, dosing with azilsartan starting on post-natal day 14 (equivalent to a neonate with morphologically and functionally immature kidneys) resulted in increased incidence of edema of the renal papilla at the end of 4-week recovery period that was non-reversible. These findings occurred in the high-dose group (10 mg/kg) and were not observed in juvenile rats dosed starting on post-natal day 21 (equivalent to a human approximately 2 years of age) or adult rats."],"effective_time":"20240123","clinical_studies":["14 CLINICAL STUDIES The antihypertensive effects of Edarbi have been demonstrated in a total of seven double-blind, randomized studies, which included five placebo-controlled and four active comparator-controlled studies (not mutually exclusive). The studies ranged from six weeks to six months in duration, at doses ranging from 20 mg to 80 mg once daily. A total of 5941 patients (3672 given Edarbi, 801 given placebo, and 1468 given active comparator) with mild, moderate or severe hypertension were studied. Overall, 51% of patients were male and 26% were 65 years or older; 67% were white and 19% were black. Two 6-week, randomized, double-blind studies compared the effect on blood pressure of Edarbi at doses of 40 mg and 80 mg, with placebo and with active comparators. Blood pressure reductions compared to placebo based on clinic blood pressure measurements at trough and 24-hour mean blood pressure by ambulatory blood pressure monitoring (ABPM) are shown in Table 1 for both studies. Edarbi, 80 mg, was statistically superior to placebo and active comparators for both clinic and 24-hour mean blood pressure measurements. Table 1. Placebo Corrected Mean Change from Baseline in Systolic/Diastolic Blood Pressure at 6 Weeks (mm Hg) Study 1 N=1285 Study 2 N=989 Clinic Blood Pressure (Mean Baseline 157.4/92.5) 24 Hour Mean by ABPM (Mean Baseline 144.9/88.7) Clinic Blood Pressure (Mean Baseline 159.0/91.8) 24 Hour Mean by ABPM (Mean Baseline 146.2/87.6) Edarbi 40 mg -14.6/-6.2 -13.2/-8.6 -12.4/-7.1 -12.1/-7.7 Edarbi 80 mg -14.9/-7.5 -14.3/-9.4 -15.5/-8.6 -13.2/-7.9 Olmesartan 40 mg -11.4/-5.3 -11.7/-7.7 -12.8/-7.1 -11.2/-7.0 Valsartan 320 mg -9.5/-4.4 -10.0/-7.0 In a study comparing Edarbi to valsartan over 24 weeks, similar results were observed. Most of the antihypertensive effect occurs within the first two weeks of dosing. Figure 2 shows the 24-hour ambulatory systolic and diastolic blood pressure profiles at endpoint. Figure 2. Mean Ambulatory Blood Pressure at 6 Weeks by Dose and Hour Other studies showed similar 24-hour ambulatory blood pressure profiles. Edarbi has a sustained and consistent antihypertensive effect during long-term treatment, as shown in a study that randomized patients to placebo or continued Edarbi after 26 weeks. No rebound effect was observed following the abrupt cessation of Edarbi therapy. Edarbi was effective in reducing blood pressure regardless of the age, gender, or race of patients, but the effect, as monotherapy, was smaller, approximately half, in black patients, who tend to have low renin levels. This has been generally true for other angiotensin II antagonists and ACE inhibitors. Edarbi has about its usual blood pressure lowering effect size when added to a calcium channel blocker (amlodipine) or a thiazide-type diuretic (chlorthalidone). There are no trials of Edarbi demonstrating reductions in cardiovascular risk in patients with hypertension, but at least one pharmacologically similar drug has demonstrated such benefits. Figure 2"],"pharmacodynamics":["12.2 Pharmacodynamics Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. An azilsartan single dose equivalent to 32 mg azilsartan medoxomil inhibited the maximal pressor effect by approximately 90% at peak, and approximately 60% at 24 hours. Plasma angiotensin I and II concentrations and plasma renin activity increased while plasma aldosterone concentrations decreased after single and repeated administration of Edarbi to healthy subjects; no clinically significant effects on serum potassium or sodium were observed. Effect on Cardiac Repolarization A thorough QT/QTc study was conducted to assess the potential of azilsartan to prolong the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320 mg of Edarbi."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Azilsartan medoxomil is hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption. Azilsartan medoxomil is not detected in plasma after oral administration. Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing. The estimated absolute bioavailability of azilsartan following administration of azilsartan medoxomil is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma concentrations (C max ) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan. Distribution The volume of distribution of azilsartan is approximately 16 L. Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well above the range achieved with recommended doses. In rats, minimal azilsartan-associated radioactivity crossed the blood-brain barrier. Azilsartan passed across the placental barrier in pregnant rats and was distributed to the fetus. Metabolism and Elimination Azilsartan is metabolized to two primary metabolites. The major metabolite in plasma is formed by O -dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately 50% and less than 1% of azilsartan, respectively. M-I and M-II do not contribute to the pharmacologic activity of Edarbi. The major enzyme responsible for azilsartan metabolism is CYP2C9. Following an oral dose of 14 C-labeled azilsartan medoxomil, approximately 55% of radioactivity was recovered in feces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min. Steady-state levels of azilsartan are achieved within five days, and no accumulation in plasma occurs with repeated once-daily dosing. Specific Populations The effect of demographic and functional factors on the pharmacokinetics of azilsartan was studied in single and multiple dose studies. Pharmacokinetic measures indicating the magnitude of the effect on azilsartan are presented in Figure 1 as change relative to reference (test/reference). Effects are modest and do not call for dosage adjustment. Figure 1. Impact of intrinsic factors on the pharmacokinetics of azilsartan Figure 1 Drug Interactions No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin. Therefore, Edarbi may be used concomitantly with these medications ."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reaction in adults was diarrhea (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 4814 patients were evaluated for safety when treated with Edarbi at doses of 20, 40, or 80 mg in clinical trials. This includes 1704 patients treated for at least six months; of these, 588 were treated for at least one year. Treatment with Edarbi was well-tolerated with an overall incidence of adverse reactions similar to placebo. The rate of withdrawals due to adverse events in placebo-controlled monotherapy and combination therapy trials was 2.4% (19/801) for placebo, 2.2% (24/1072) for Edarbi 40 mg, and 2.7% (29/1074) for Edarbi 80 mg. The most common adverse event leading to discontinuation, hypotension/orthostatic hypotension, was reported by 0.4% (8/2146) patients randomized to Edarbi 40 mg or 80 mg compared to 0% (0/801) patients randomized to placebo. Generally, adverse reactions were mild, not dose related, and similar regardless of age, gender, and race. In placebo-controlled monotherapy trials, diarrhea was reported up to 2% in patients treated with Edarbi 80 mg daily compared with 0.5% of patients on placebo. Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of ≥0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below: Gastrointestinal Disorders: nausea General Disorders and Administration Site Conditions: asthenia, fatigue Musculoskeletal and Connective Tissue Disorders: muscle spasm Nervous System Disorders: dizziness, dizziness postural Respiratory, Thoracic, and Mediastinal Disorders: cough 6.2 Postmarketing Experience The following adverse reactions have been identified during the postmarketing use of EDARBI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Rash Pruritus Angioedema"],"contraindications":["4 CONTRAINDICATIONS Do not coadminister aliskiren-containing products with Edarbi in patients with diabetes [see Drug Interactions (7) ] . Do not coadminister aliskiren-containing products with Edarbi in patients with diabetes. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. ( 7 ) Lithium: Increases in serum lithium concentrations and lithium toxicity. ( 7 ) 7.1 Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors. 7.2 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbi and other agents that affect the RAS. Do not coadminister aliskiren with Edarbi in patients with diabetes. Avoid use of aliskiren with Edarbi in patients with renal impairment (GFR <60 mL/min). 7.3 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor agonists. Monitor serum lithium levels during concomitant use."],"how_supplied_table":["<table width=\"30%\"><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"60%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\" rowspan=\"2\">Tablet</th><th styleCode=\"Rrule\" align=\"left\">NDC 60631-xxx-xx</th></tr><tr><th styleCode=\"Rrule\" align=\"center\">Bottle/30</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\">40 mg</td><td styleCode=\"Rrule\">040-30</td></tr><tr><td styleCode=\"Lrule Rrule\">80 mg</td><td styleCode=\"Rrule\">080-30</td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis. An AT 2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure."],"storage_and_handling":["Storage Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed. Protect from moisture and light. Do not repackage; dispense and store in original container."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the active moiety, azilsartan. Azilsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis. An AT 2 receptor is also found in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Azilsartan has more than a 10,000-fold greater affinity for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction catalyzed by ACE. Because azilsartan does not inhibit ACE (kinase II), it should not affect bradykinin levels. Whether this difference has clinical relevance is not yet known. Azilsartan does not bind to or block other receptors or ion channels known to be important in cardiovascular regulation. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of azilsartan on blood pressure. 12.2 Pharmacodynamics Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. An azilsartan single dose equivalent to 32 mg azilsartan medoxomil inhibited the maximal pressor effect by approximately 90% at peak, and approximately 60% at 24 hours. Plasma angiotensin I and II concentrations and plasma renin activity increased while plasma aldosterone concentrations decreased after single and repeated administration of Edarbi to healthy subjects; no clinically significant effects on serum potassium or sodium were observed. Effect on Cardiac Repolarization A thorough QT/QTc study was conducted to assess the potential of azilsartan to prolong the QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320 mg of Edarbi. 12.3 Pharmacokinetics Absorption Azilsartan medoxomil is hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption. Azilsartan medoxomil is not detected in plasma after oral administration. Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of 20 mg to 320 mg after single or multiple dosing. The estimated absolute bioavailability of azilsartan following administration of azilsartan medoxomil is approximately 60%. After oral administration of azilsartan medoxomil, peak plasma concentrations (C max ) of azilsartan are reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan. Distribution The volume of distribution of azilsartan is approximately 16 L. Azilsartan is highly bound to human plasma proteins (>99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well above the range achieved with recommended doses. In rats, minimal azilsartan-associated radioactivity crossed the blood-brain barrier. Azilsartan passed across the placental barrier in pregnant rats and was distributed to the fetus. Metabolism and Elimination Azilsartan is metabolized to two primary metabolites. The major metabolite in plasma is formed by O -dealkylation, referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately 50% and less than 1% of azilsartan, respectively. M-I and M-II do not contribute to the pharmacologic activity of Edarbi. The major enzyme responsible for azilsartan metabolism is CYP2C9. Following an oral dose of 14 C-labeled azilsartan medoxomil, approximately 55% of radioactivity was recovered in feces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan. The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately 2.3 mL/min. Steady-state levels of azilsartan are achieved within five days, and no accumulation in plasma occurs with repeated once-daily dosing. Specific Populations The effect of demographic and functional factors on the pharmacokinetics of azilsartan was studied in single and multiple dose studies. Pharmacokinetic measures indicating the magnitude of the effect on azilsartan are presented in Figure 1 as change relative to reference (test/reference). Effects are modest and do not call for dosage adjustment. Figure 1. Impact of intrinsic factors on the pharmacokinetics of azilsartan Figure 1 Drug Interactions No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin. Therefore, Edarbi may be used concomitantly with these medications ."],"indications_and_usage":["1 INDICATIONS AND USAGE Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. Edarbi is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Edarbi may be used either alone or in combination with other antihypertensive agents. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Correct volume or salt depletion prior to administration of Edarbi. ( 5.2 ) Monitor for worsening renal function in patients with renal impairment. ( 5.3 ) 5.1 Fetal Toxicity Edarbi can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Edarbi as soon as possible [see Use in Specific Populations (8.1) ]. 5.2 Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Edarbi. Correct volume or salt depletion prior to administration of Edarbi, or start treatment at 40 mg. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline . A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. 5.3 Impaired Renal Function As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with Edarbi. In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death. Similar results may be anticipated in patients treated with Edarbi [see Drug Interactions (7) , Use in Specific Populations (8.6) , and Clinical Pharmacology (12.3) ]. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of Edarbi in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected."],"clinical_studies_table":["<table width=\"75%\" ID=\"table1\"><caption>Table 1. Placebo Corrected Mean Change from Baseline in Systolic/Diastolic Blood Pressure at 6 Weeks (mm Hg)</caption><col width=\"20%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><thead><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\" colspan=\"2\">Study 1 N=1285</th><th styleCode=\"Rrule\" colspan=\"2\">Study 2 N=989</th></tr><tr styleCode=\"Botrule\"><th styleCode=\"Lrule Rrule\"/><th styleCode=\"Rrule\">Clinic Blood Pressure (Mean Baseline 157.4/92.5)</th><th styleCode=\"Rrule\">24 Hour Mean by ABPM (Mean Baseline 144.9/88.7)</th><th styleCode=\"Rrule\">Clinic Blood Pressure (Mean Baseline 159.0/91.8)</th><th styleCode=\"Rrule\">24 Hour Mean by ABPM (Mean Baseline 146.2/87.6)</th></tr></thead><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Edarbi 40 mg</content></td><td styleCode=\"Rrule\">-14.6/-6.2</td><td styleCode=\"Rrule\">-13.2/-8.6</td><td styleCode=\"Rrule\">-12.4/-7.1</td><td styleCode=\"Rrule\">-12.1/-7.7</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Edarbi 80 mg</content></td><td styleCode=\"Rrule\">-14.9/-7.5</td><td styleCode=\"Rrule\">-14.3/-9.4</td><td styleCode=\"Rrule\">-15.5/-8.6</td><td styleCode=\"Rrule\">-13.2/-7.9</td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Olmesartan 40 mg</content></td><td styleCode=\"Rrule\">-11.4/-5.3</td><td styleCode=\"Rrule\">-11.7/-7.7</td><td styleCode=\"Rrule\">-12.8/-7.1</td><td styleCode=\"Rrule\">-11.2/-7.0</td></tr><tr><td styleCode=\"Lrule Rrule\"><content styleCode=\"bold\">Valsartan 320 mg</content></td><td styleCode=\"Rrule\">-9.5/-4.4</td><td styleCode=\"Rrule\">-10.0/-7.0</td><td styleCode=\"Rrule\"/><td styleCode=\"Rrule\"/></tr></tbody></table>","<table width=\"100%\" styleCode=\"Noautorules\"><col width=\"100%\" align=\"center\" valign=\"top\"/><tbody><tr><td><content styleCode=\"bold\">Figure 2. Mean Ambulatory Blood Pressure at 6 Weeks by Dose and Hour </content></td></tr><tr><td><renderMultiMedia referencedObject=\"MM3\"/></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Azilsartan medoxomil was not carcinogenic when assessed in 26-week transgenic (Tg.rasH2) mouse and two-year rat studies. The highest doses tested (450 mg azilsartan medoxomil/kg/day in the mouse and 600 mg azilsartan medoxomil/kg/day in the rat) produced exposures to azilsartan that are 12 (mice) and 27 (rats) times the average exposure to azilsartan in humans given the maximum recommended human dose (MRHD, 80 mg azilsartan medoxomil/day). M-II was not carcinogenic when assessed in 26-week Tg.rasH2 mouse and two-year rat studies. The highest doses tested (approximately 8000 mg M-II/kg/day [males] and 11,000 mg M-II/kg/day [females] in the mouse and 1000 mg M-II/kg/day [males] and up to 3000 mg M-II/kg/day [females] in the rat) produced exposures that are, on average, about 30 (mice) and seven (rats) times the average exposure to M-II in humans at the MRHD. Mutagenesis Azilsartan medoxomil, azilsartan, and M-II were positive for structural aberrations in the Chinese Hamster Lung Cytogenetic Assay. In this assay, structural chromosomal aberrations were observed with the prodrug, azilsartan medoxomil, without metabolic activation. The active moiety, azilsartan was also positive in this assay both with and without metabolic activation. The major human metabolite, M-II was also positive in this assay during a 24-hour assay without metabolic activation. Azilsartan medoxomil, azilsartan, and M-II were devoid of genotoxic potential in the Ames reverse mutation assay with Salmonella typhimurium and Escherichia coli , the in vitro Chinese Hamster Ovary Cell forward mutation assay, the in vitro mouse lymphoma (tk) gene mutation test, the ex vivo unscheduled DNA synthesis test, and the in vivo mouse and/or rat bone marrow micronucleus assay. Impairment of Fertility There was no effect of azilsartan medoxomil on the fertility of male or female rats at oral doses of up to 1000 mg azilsartan medoxomil/kg/day (6000 mg/m 2 [approximately 122 times the MRHD of 80 mg azilsartan medoxomil/60 kg on a mg/m 2 basis]). Fertility of rats also was unaffected at doses of up to 3000 mg M-II/kg/day."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) Pregnancy Tell female patients of childbearing potential about the consequences of exposure to Edarbi during pregnancy. Discuss treatment options with women planning to become pregnant. Tell patients to report pregnancies to their physicians as soon as possible."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended dose in adults is 80 mg taken once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. ( 2.1 ) Edarbi may be administered with or without food. ( 2.1 ) Edarbi may be administered with other antihypertensive agents. ( 2.1 ) 2.1 Recommended Dose The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. 2.2 Handling Instructions Do not repackage Edarbi. Dispense and store Edarbi in its original container to protect Edarbi from light and moisture."],"spl_product_data_elements":["Edarbi Azilsartan kamedoxomil Azilsartan kamedoxomil Azilsartan Azilsartan medoxomil mannitol fumaric acid sodium hydroxide HYDROXYPROPYL CELLULOSE (1600000 WAMW) croscarmellose sodium MICROCRYSTALLINE CELLULOSE magnesium stearate White to nearly white ASL;40 Edarbi Azilsartan kamedoxomil Azilsartan kamedoxomil Azilsartan Azilsartan medoxomil mannitol fumaric acid sodium hydroxide HYDROXYPROPYL CELLULOSE (1600000 WAMW) croscarmellose sodium MICROCRYSTALLINE CELLULOSE magnesium stearate White to nearly white ASL;80"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Edarbi is supplied as white to nearly white round tablets in the following dosage strengths: 40-mg tablets – debossed \"ASL\" on one side and \"40\" on the other 80-mg tablets – debossed \"ASL\" on one side and \"80\" on the other Tablets: 40 mg and 80 mg. ( 3 )"],"spl_patient_package_insert":["Patient Information Edarbi (eh-DAR-bee) (azilsartan medoxomil) Tablets Read this Patient Information leaflet before you start taking Edarbi and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. What is the most important information I should know about Edarbi? Edarbi can cause harm or death to your unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you become pregnant while taking Edarbi, tell your doctor right away. Your doctor may switch you to a different medicine to treat your high blood pressure. What is Edarbi? Edarbi is a prescription medicine called an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension) in adults. Your doctor may prescribe other medicines for you to take along with Edarbi to treat your high blood pressure. It is not known if Edarbi is safe and effective in children under 18 years of age. What should I tell my doctor before taking Edarbi? Before you take Edarbi, tell your doctor if you: have been told that you have abnormal body salt (electrolytes) levels in your blood are pregnant or plan to become pregnant. See \" What is the most important information I should know about Edarbi? \" are breastfeeding or plan to breastfeed. It is not known if Edarbi passes into your breast milk. You and your doctor should decide if you will take Edarbi or breastfeed. You should not do both. Talk with your doctor about the best way to feed your baby if you take Edarbi. Tell your doctor about all the medicines you take , including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take: other medicines used to treat your high blood pressure or heart problem water pills (diuretic) Ask your doctor if you are not sure if you are taking a medicine listed above. Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist when you get a new medicine. How should I take Edarbi? Your doctor will tell you how much Edarbi to take and when to take it. Follow his/her instructions. Edarbi can be taken with or without food. If you take too much Edarbi, call your doctor or go to the nearest hospital emergency room right away. What are the possible side effects of Edarbi? Edarbi may cause side effects, including: Harm or death to your unborn fetus if taken in the second or third trimester. See \" What is the most important information I should know about Edarbi? \" Low blood pressure (hypotension) and dizziness is most likely to happen if you also: take water pills (diuretics) are on a low-salt diet take other medicines that affect your blood pressure get sick with vomiting or diarrhea do not drink enough fluids If you feel faint or dizzy, lie down and call your doctor right away. These are not all the possible side effects with Edarbi. Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How do I store Edarbi? Store Edarbi at 59°F to 86°F (15°C to 30°C). Store Edarbi in the original container that you received from your pharmacist or doctor. Do not put Edarbi into a different container. Keep Edarbi in a tightly closed container, and keep Edarbi out of the light. Keep Edarbi and all medicines out of the reach of children. General information about Edarbi. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not give Edarbi to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about Edarbi. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Edarbi that is written for health professionals. For more information, go to www.edarbi.com or call 1-800-461-7449. What is high blood pressure (hypertension)? Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too great. High blood pressure makes the heart work harder to pump blood through the body and causes damage to the blood vessels. Edarbi tablets can help your blood vessels relax so your blood pressure is lower. Medicines that lower your blood pressure may lower your chance of having a stroke or heart attack. What are the ingredients in Edarbi? Active ingredient: azilsartan medoxomil Inactive ingredients: mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, and magnesium stearate. Manufactured by: Takeda Ireland Manufactured for: azurity ® pharmaceuticals Woburn, MA 01801 Patent: https://azurity.com/patents_and_trademarks/ This product's labeling may have been updated. For current Full Prescribing Information, please visit www.edarbi.com Edarbi is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Azurity Pharmaceuticals, Inc. EB-PI-09 Rev. Jan2024"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding is not recommended. ( 8.2 ) Geriatric Patients: Abnormally high serum creatinine values were more likely to be reported for patients age 75 or older. No overall difference in efficacy versus younger patients, but greater sensitivity of some older individuals cannot be ruled out. ( 8.5 ) In patients with an activated renin-angiotensin system, as by volume- or salt-depletion, renin-angiotensin-aldosterone system (RAAS) blockers such as azilsartan medoxomil can cause excessive hypotension. In susceptible patients, e.g., with renal artery stenosis, RAAS blockers can cause renal failure ( 5.2 , 5.3 ). 8.1 Pregnancy Risk Summary Edarbi can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death ( see Clinical Considerations ). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. When pregnancy is detected, discontinue Edarbi as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension and death. Perform serial ultrasound examinations to assess the intra-amniotic environment. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to Edarbi for hypotension, oliguria, and hyperkalemia. In neonates with a history of in utero exposure to Edarbi, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function . Data Animal Data In peri- and postnatal rat development studies, adverse effects on pup viability, delayed incisor eruption and dilatation of the renal pelvis along with hydronephrosis were seen when azilsartan medoxomil was administered to pregnant and nursing rats at 1.2 times the MRHD on a mg/m 2 basis. Reproductive toxicity studies indicated that azilsartan medoxomil was not teratogenic when administered at oral doses up to 1000 mg azilsartan medoxomil/kg/day to pregnant rats (122 times the MRHD on a mg/m 2 basis) or up to 50 mg azilsartan medoxomil/kg/day to pregnant rabbits (12 times the MRHD on a mg/m 2 basis). M-II also was not teratogenic in rats or rabbits at doses up to 3000 mg M-II/kg/day. Azilsartan crossed the placenta and was found in the fetuses of pregnant rats and was excreted into the milk of lactating rats. 8.2 Lactation Risk Summary There is limited information regarding the presence of azilsartan in human milk, the effects on the breastfed infant, or the effects on milk production. Azilsartan is present in rat milk. Because of the potential for adverse effects on the nursing infant, advise a nursing woman that breastfeeding is not recommended during treatment with Edarbi . 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Use of Edarbi is not recommended in children less than 2 years of age. It is not known whether post-natal use of azilsartan in patients less than 2 years of age, before maturation of kidney function is complete, has a long-term deleterious effect on the kidney. Juvenile Animal Studies In juvenile rat studies, dosing with azilsartan starting on post-natal day 14 (equivalent to a neonate with morphologically and functionally immature kidneys) resulted in increased incidence of edema of the renal papilla at the end of 4-week recovery period that was non-reversible. These findings occurred in the high-dose group (10 mg/kg) and were not observed in juvenile rats dosed starting on post-natal day 21 (equivalent to a human approximately 2 years of age) or adult rats. 8.5 Geriatric Use No dose adjustment with Edarbi is necessary in elderly patients. Of the total patients in clinical studies with Edarbi, 26% were elderly (65 years of age and older); 5% were 75 years of age and older. Abnormally high serum creatinine values were more likely to be reported for patients age 75 or older. No other differences in safety or effectiveness were observed between elderly patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3) ] . 8.6 Renal Impairment Dose adjustment is not required in patients with mild-to-severe renal impairment or end-stage renal disease. Patients with moderate to severe renal impairment are more likely to report abnormally high serum creatinine values. 8.7 Hepatic Impairment No dose adjustment is necessary for subjects with mild or moderate hepatic impairment. Edarbi has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3) ]."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Label NDC 60631-040-30 30 Tablets edarbi (azilsartan medoxomil) tablets 40 mg Rx Only PRINCIPAL DISPLAY PANEL - 40 mg Tablet Bottle Label","PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label NDC 60631-080-30 30 Tablets edarbi (azilsartan medoxomil) tablets 80 mg Rx Only PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Azilsartan medoxomil was not carcinogenic when assessed in 26-week transgenic (Tg.rasH2) mouse and two-year rat studies. The highest doses tested (450 mg azilsartan medoxomil/kg/day in the mouse and 600 mg azilsartan medoxomil/kg/day in the rat) produced exposures to azilsartan that are 12 (mice) and 27 (rats) times the average exposure to azilsartan in humans given the maximum recommended human dose (MRHD, 80 mg azilsartan medoxomil/day). M-II was not carcinogenic when assessed in 26-week Tg.rasH2 mouse and two-year rat studies. The highest doses tested (approximately 8000 mg M-II/kg/day [males] and 11,000 mg M-II/kg/day [females] in the mouse and 1000 mg M-II/kg/day [males] and up to 3000 mg M-II/kg/day [females] in the rat) produced exposures that are, on average, about 30 (mice) and seven (rats) times the average exposure to M-II in humans at the MRHD. Mutagenesis Azilsartan medoxomil, azilsartan, and M-II were positive for structural aberrations in the Chinese Hamster Lung Cytogenetic Assay. In this assay, structural chromosomal aberrations were observed with the prodrug, azilsartan medoxomil, without metabolic activation. The active moiety, azilsartan was also positive in this assay both with and without metabolic activation. The major human metabolite, M-II was also positive in this assay during a 24-hour assay without metabolic activation. Azilsartan medoxomil, azilsartan, and M-II were devoid of genotoxic potential in the Ames reverse mutation assay with Salmonella typhimurium and Escherichia coli , the in vitro Chinese Hamster Ovary Cell forward mutation assay, the in vitro mouse lymphoma (tk) gene mutation test, the ex vivo unscheduled DNA synthesis test, and the in vivo mouse and/or rat bone marrow micronucleus assay. Impairment of Fertility There was no effect of azilsartan medoxomil on the fertility of male or female rats at oral doses of up to 1000 mg azilsartan medoxomil/kg/day (6000 mg/m 2 [approximately 122 times the MRHD of 80 mg azilsartan medoxomil/60 kg on a mg/m 2 basis]). Fertility of rats also was unaffected at doses of up to 3000 mg M-II/kg/day."]},"tags":[{"label":"Angiotensin 2 Receptor Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Type-1 angiotensin II receptor","category":"target"},{"label":"AGTR1","category":"gene"},{"label":"C09CA09","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Arbor Pharms Ireland","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Angiotensin II Type 1 Receptor Blockers","category":"pharmacology"},{"label":"Angiotensin Receptor Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Edarbi as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )"],"safetySignals":[{"llr":175.418,"date":"","count":80,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 80 times (LLR=175)"},{"llr":162.917,"date":"","count":88,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 88 times (LLR=163)"},{"llr":136.361,"date":"","count":107,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=136)"},{"llr":102.606,"date":"","count":78,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 78 times (LLR=103)"},{"llr":73.317,"date":"","count":41,"signal":"Proteinuria","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=73)"},{"llr":71.169,"date":"","count":19,"signal":"Product odour abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=71)"},{"llr":64.964,"date":"","count":79,"signal":"Platelet count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 79 times (LLR=65)"},{"llr":63.598,"date":"","count":69,"signal":"Cardiac failure","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=64)"},{"llr":63.553,"date":"","count":41,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 41 times (LLR=64)"},{"llr":63.298,"date":"","count":106,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=63)"},{"llr":61.467,"date":"","count":16,"signal":"Thalamus haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=61)"},{"llr":56.676,"date":"","count":9,"signal":"Fibrillary glomerulonephritis","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=57)"},{"llr":53.609,"date":"","count":34,"signal":"Palmar-plantar erythrodysaesthesia syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=54)"},{"llr":46.849,"date":"","count":49,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=47)"},{"llr":42.484,"date":"","count":40,"signal":"Liver disorder","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=42)"}],"commonSideEffects":[{"effect":"diarrhea","drugRate":"2%","_validated":true,"placeboRate":"0.5%"}],"contraindications":["Do not coadminister aliskiren-containing products with Edarbi in patients with diabetes."],"specialPopulations":{"Lactation":"There is limited information regarding the presence of azilsartan in human milk, the effects on the breastfed infant, or the effects on milk production. Azilsartan is present in rat milk. Thiazide-like diuretics like chlorthalidone are excreted in human milk. Because of the potential for adverse effects on the nursing infant, advise nursing woman that breastfeeding is not recommended during treatment with Edarbyclor.","Pregnancy":"Edarbyclor can cause fetal harm when administered to pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.","Geriatric use":"No dose adjustment with Edarbi is necessary in elderly patients. Of the total patients in clinical studies with Edarbi, 26% were elderly (65 years of age and older); 5% were 75 years of age and older.","Paediatric use":"Safety and effectiveness of Edarbyclor in pediatric patients under 18 years of age have not been established."},"discontinuationRates":[{"trial":"placebo-controlled monotherapy and combination therapy trials","drugArm":"2.2% (24/1072) for Edarbi 40 mg, and 2.7% (29/1074) for Edarbi 80 mg","placeboArm":"2.4% (19/801)","commonReason":"hypotension/orthostatic hypotension (0.4% (8/2146) patients randomized to Edarbi 40 mg or 80 mg)"}]},"trials":[],"aliases":[],"company":"Arbor Pharms Ireland","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2031-07-01","territory":"US","patentNumber":"9387249"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-02-04","territory":"US","patentNumber":"9169238"},{"source":"FDA Orange Book via DrugCentral","expires":"2028-03-26","territory":"US","patentNumber":"9066936"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-05-22","territory":"US","patentNumber":"7157584"},{"source":"FDA Orange Book via DrugCentral","expires":"2025-01-07","territory":"US","patentNumber":"7572920"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AZILSARTAN MEDOXOMIL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:03:50.888290+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T02:03:50.888201+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:03:56.025329+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T02:03:50.961037+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZILSARTAN MEDOXOMIL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:03:56.505234+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:49.413396+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue Edarbi as soon as pos","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:49.413426+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzymes (ACE, kinase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases during absorption to the activ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:10.228145+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2028661/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:03:57.213115+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The most common adverse reaction in adults was diarrhea (2%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect th","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:21.780300+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:04:24.340988+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA200796","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:03:49.413430+00:00"}},"allNames":"edarbi","offLabel":[],"synonyms":["TAK 491","edarbi","azilsartan medoxomil","azilsartan kamedoxomil"],"timeline":[{"date":"2001-01-18","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Takeda Pharmaceutical Company Limited)"},{"date":"2011-02-25","type":"positive","source":"DrugCentral","milestone":"FDA approval (Arbor Pharms Ireland)"},{"date":"2011-12-07","type":"positive","source":"DrugCentral","milestone":"EMA approval (Takeda Pharma A/S)"}],"brandName":"Edarbi","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"AT1 receptor","novelty":"Follow-on","targets":[{"gene":"AGTR1","source":"DrugCentral","target":"Type-1 angiotensin II receptor","protein":"Type-1 angiotensin II receptor"}],"moaClass":"Angiotensin 2 Type 1 Receptor Antagonists","modality":"Small molecule","drugClass":"Angiotensin 2 Receptor Blocker","explanation":"Azilsartan works by blocking the effects of angiotensin II, a hormone that causes blood vessels to narrow and increases blood pressure. By binding to the AT1 receptor, azilsartan prevents these effects, leading to lower blood pressure.","oneSentence":"Azilsartan blocks angiotensin II's vasoconstrictor and aldosterone-secreting effects by selectively binding to the AT1 receptor.","technicalDetail":"Azilsartan medoxomil is a prodrug that is converted to azilsartan, which selectively blocks the binding of angiotensin II to the AT1 receptor in tissues like vascular smooth muscle and the adrenal gland. This blockade is independent of the pathway for angiotensin II synthesis and does not affect bradykinin levels."},"commercial":{"launchDate":"2011","_launchSource":"DrugCentral (FDA 2011-02-25, ARBOR PHARMS IRELAND)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4322","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AZILSARTAN%20MEDOXOMIL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AZILSARTAN MEDOXOMIL","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T08:52:30.085540","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:04:27.600761+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"losartan","drugSlug":"losartan","fdaApproval":"1995-04-14","patentExpiry":"Oct 7, 2041","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"eprosartan","drugSlug":"eprosartan","fdaApproval":"1997-12-22","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valsartan","drugSlug":"valsartan","fdaApproval":"1996-12-23","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"irbesartan","drugSlug":"irbesartan","fdaApproval":"1997-09-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telmisartan","drugSlug":"telmisartan","fdaApproval":"1998-11-10","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"olmesartan medoxomil","drugSlug":"olmesartan-medoxomil","fdaApproval":"2002-04-25","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"azilsartan medoxomil","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"losartan","brandName":"losartan","genericName":"losartan","approvalYear":"1995","relationship":"same-class"},{"drugId":"eprosartan","brandName":"eprosartan","genericName":"eprosartan","approvalYear":"1997","relationship":"same-class"},{"drugId":"valsartan","brandName":"valsartan","genericName":"valsartan","approvalYear":"1996","relationship":"same-class"},{"drugId":"irbesartan","brandName":"irbesartan","genericName":"irbesartan","approvalYear":"1997","relationship":"same-class"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-class"},{"drugId":"telmisartan","brandName":"telmisartan","genericName":"telmisartan","approvalYear":"1998","relationship":"same-class"},{"drugId":"olmesartan-medoxomil","brandName":"olmesartan medoxomil","genericName":"olmesartan medoxomil","approvalYear":"2002","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":["Post-stroke Pneumonia"],"enrollment":13656,"completionDate":"2026-08-19"},{"nctId":"NCT05107960","phase":"","title":"A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-12-16","conditions":["Hypertension"],"enrollment":5,"completionDate":"2024-08-31"},{"nctId":"NCT06990204","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)","status":"NOT_YET_RECRUITING","sponsor":"Gedeon Richter Plc.","startDate":"2025-06-06","conditions":["Hypertension"],"enrollment":56,"completionDate":"2025-07-01"},{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":["Hypertension"],"enrollment":377,"completionDate":"2019-11-11"},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":["Sacubitril/Valsartan","Hypertension","Obesity"],"enrollment":180,"completionDate":"2027-06-30"},{"nctId":"NCT04668157","phase":"PHASE3","title":"A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-05-17","conditions":["Hypertension"],"enrollment":10,"completionDate":"2023-12-28"},{"nctId":"NCT06618079","phase":"PHASE1","title":"Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huons Co., Ltd.","startDate":"2024-04-20","conditions":["Hypertension"],"enrollment":46,"completionDate":"2024-10-01"},{"nctId":"NCT05947448","phase":"","title":"Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study","status":"UNKNOWN","sponsor":"Hasten Biopharmaceutical Co., Ltd.","startDate":"2024-01-22","conditions":["Essential Hypertension"],"enrollment":1215,"completionDate":"2025-12-31"},{"nctId":"NCT04470817","phase":"","title":"A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2018-08-07","conditions":["Essential Hypertension"],"enrollment":3438,"completionDate":"2023-05-25"},{"nctId":"NCT04470830","phase":"","title":"A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2019-09-11","conditions":["Essential Hypertension"],"enrollment":718,"completionDate":"2023-05-25"},{"nctId":"NCT05841654","phase":"PHASE4","title":"Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension","status":"UNKNOWN","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-06-01","conditions":["Hypertension","Atrial Fibrillation"],"enrollment":400,"completionDate":"2025-10-01"},{"nctId":"NCT05753696","phase":"NA","title":"Azilsartan in Patients With Diabetic Kidney Disease and Hypertension","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-01","conditions":["Proteinuria","Kidney Dysfunction","Blood Pressure","Diabetic Kidney Disease"],"enrollment":106,"completionDate":"2024-12-30"},{"nctId":"NCT04606563","phase":"PHASE3","title":"Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?","status":"TERMINATED","sponsor":"University of British Columbia","startDate":"2020-10-09","conditions":["Covid19","SARS-CoV Infection"],"enrollment":341,"completionDate":"2022-04-22"},{"nctId":"NCT03539627","phase":"","title":"Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.","status":"COMPLETED","sponsor":"Research Institute for Complex Problems of Cardiovascular Diseases, Russia","startDate":"2018-11-07","conditions":["Arterial Hypertension","Diabetes Mellitus","Stable Chronic Angina"],"enrollment":184,"completionDate":"2022-04-29"},{"nctId":"NCT05002244","phase":"PHASE1","title":"A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Celltrion","startDate":"2021-07-23","conditions":["Health, Subjective"],"enrollment":37,"completionDate":"2021-09-13"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT04743063","phase":"","title":"Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-01-14","conditions":["Heart Failure, Systolic","Frailty"],"enrollment":40000,"completionDate":"2022-12-31"},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":["Arterial Hypertension"],"enrollment":94,"completionDate":"2020-03-31"},{"nctId":"NCT02791438","phase":"PHASE3","title":"A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-18","conditions":["Pediatric Hypertension"],"enrollment":27,"completionDate":"2019-06-04"},{"nctId":"NCT02541669","phase":"PHASE1","title":"A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-11-20","conditions":["Healthy Volunteer"],"enrollment":64,"completionDate":"2017-03-17"},{"nctId":"NCT02756819","phase":"","title":"International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-18","conditions":["Hypertension"],"enrollment":1945,"completionDate":"2018-05-08"},{"nctId":"NCT03434977","phase":"PHASE1","title":"A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-14","conditions":["Healthy Volunteers"],"enrollment":12,"completionDate":"2018-03-11"},{"nctId":"NCT02181816","phase":"","title":"Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06-26","conditions":["Hypertension"],"enrollment":1090,"completionDate":"2017-01-31"},{"nctId":"NCT02100319","phase":"","title":"Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance \"Hypertension Complicated by Diabetes \"","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-03-03","conditions":["Hypertension"],"enrollment":387,"completionDate":"2016-02-29"},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":["Essential Hypertension"],"enrollment":612,"completionDate":"2017-10-13"},{"nctId":"NCT02517866","phase":"PHASE4","title":"Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-07-13","conditions":["Essential Hypertension","Type 2 Diabetes Mellitus"],"enrollment":380,"completionDate":"2016-11-25"},{"nctId":"NCT02092025","phase":"","title":"Azilsartan Tablets Special Drug Use Surveillance: Long-term Use","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-06-20","conditions":["Hypertension"],"enrollment":3437,"completionDate":"2016-01-15"},{"nctId":"NCT03042299","phase":"PHASE1","title":"A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-10","conditions":["Japanese Healthy Adult Male Participants"],"enrollment":14,"completionDate":"2017-03-11"},{"nctId":"NCT02786082","phase":"PHASE1","title":"Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-11-01","conditions":["Hypertension"],"enrollment":29,"completionDate":"2017-11-30"},{"nctId":"NCT02609490","phase":"PHASE3","title":"Azilsartan in Chinese Patients With Mild and Moderate Hypertension","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2015-09","conditions":["Hypertension"],"enrollment":304,"completionDate":"2018-08"},{"nctId":"NCT03652792","phase":"PHASE1","title":"Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-01-22","conditions":["Bioequivalence of Two Azilsartan Formulations"],"enrollment":60,"completionDate":"2018-07-05"},{"nctId":"NCT01774591","phase":"NA","title":"Effect of Azilsartan on Aldosterone in Postmenopausal Females","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-01","conditions":["Hypertension"],"enrollment":21,"completionDate":"2016-01"},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":["Hypertension"],"enrollment":80,"completionDate":"2019-12-31"},{"nctId":"NCT02079805","phase":"PHASE4","title":"A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-06","conditions":["Essential Hypertension Complicated by Type 2 Diabetes Mellitus"],"enrollment":33,"completionDate":"2016-04"},{"nctId":"NCT02203916","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-07","conditions":["Hypertension"],"enrollment":328,"completionDate":"2016-02"},{"nctId":"NCT02401464","phase":"PHASE1","title":"A Bioequivalence Study of TAK-536 Pediatric Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":["Japanese Healthy Adult Males"],"enrollment":52,"completionDate":"2015-05"},{"nctId":"NCT02400775","phase":"PHASE4","title":"A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2015-03","conditions":["Essential Hypertension With Stable Angina and Dyslipidemia"],"enrollment":0,"completionDate":"2016-04"},{"nctId":"NCT02451150","phase":"PHASE3","title":"A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08","conditions":["Pediatric Hypertension"],"enrollment":6,"completionDate":"2015-09"},{"nctId":"NCT01762501","phase":"NA","title":"Azilsartan Circadian and Sleep Pressure","status":"COMPLETED","sponsor":"Sogo Rinsho Médéfi Co., Ltd.","startDate":"2012-12","conditions":["Hypertension"],"enrollment":957,"completionDate":"2013-12"},{"nctId":"NCT01496430","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-01","conditions":["Hypertension","Diabetes"],"enrollment":105,"completionDate":"2013-05"},{"nctId":"NCT02407210","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-01","conditions":["Essential Hypertension"],"enrollment":304,"completionDate":""},{"nctId":"NCT02235519","phase":"PHASE2,PHASE3","title":"Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients","status":"UNKNOWN","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2014-01","conditions":["Hypertension","Obesity","Type 2 Diabetes Mellitus"],"enrollment":300,"completionDate":"2015-06"},{"nctId":"NCT01078376","phase":"PHASE1","title":"A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2010-05","conditions":["Hypertension"],"enrollment":29,"completionDate":"2013-09"},{"nctId":"NCT01456169","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":["Essential Hypertension"],"enrollment":507,"completionDate":"2013-01"},{"nctId":"NCT02072330","phase":"PHASE2,PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":["Grade I or II Essential Hypertension"],"enrollment":353,"completionDate":"2013-12"},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":["Safety"],"enrollment":153,"completionDate":"2012-10"},{"nctId":"NCT01985152","phase":"PHASE1","title":"A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":["Health"],"enrollment":62,"completionDate":""},{"nctId":"NCT01609959","phase":"PHASE4","title":"New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering","status":"COMPLETED","sponsor":"Nara Medical University","startDate":"2012-06","conditions":["Hypertension"],"enrollment":70,"completionDate":"2013-10"},{"nctId":"NCT00760214","phase":"PHASE3","title":"Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-01","conditions":["Hypertension"],"enrollment":885,"completionDate":"2009-04"},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":["Essential Hypertension"],"enrollment":837,"completionDate":"2011-11"},{"nctId":"NCT01124656","phase":"PHASE3","title":"Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-09","conditions":["Diabetes Mellitus, Type 2"],"enrollment":26,"completionDate":"2007-05"},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":["Essential Hypertension"],"enrollment":1085,"completionDate":"2010-06"},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":["Diabetes Mellitus"],"enrollment":704,"completionDate":"2005-10"},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":["Essential Hypertension"],"enrollment":609,"completionDate":"2009-11"},{"nctId":"NCT00847626","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-01","conditions":["Hypertension"],"enrollment":1711,"completionDate":"2010-07"},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":["Essential Hypertension"],"enrollment":1071,"completionDate":"2010-11"},{"nctId":"NCT00591578","phase":"PHASE3","title":"Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-12","conditions":["Hypertension"],"enrollment":984,"completionDate":"2010-03"},{"nctId":"NCT00696384","phase":"PHASE3","title":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":["Hypertension"],"enrollment":418,"completionDate":"2009-04"},{"nctId":"NCT00696241","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":["Hypertension"],"enrollment":1275,"completionDate":"2008-10"},{"nctId":"NCT00591266","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":["Hypertension"],"enrollment":566,"completionDate":"2009-04"},{"nctId":"NCT00591773","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-09","conditions":["Hypertension"],"enrollment":551,"completionDate":"2009-03"},{"nctId":"NCT00591253","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":["Hypertension"],"enrollment":413,"completionDate":"2009-04"},{"nctId":"NCT00696436","phase":"PHASE3","title":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-04","conditions":["Hypertension"],"enrollment":1291,"completionDate":"2009-08"},{"nctId":"NCT00695955","phase":"PHASE3","title":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":["Hypertension"],"enrollment":669,"completionDate":"2010-05"},{"nctId":"NCT00362115","phase":"PHASE2","title":"Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":["Hypertension"],"enrollment":449,"completionDate":"2006-12"},{"nctId":"NCT01289132","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":["Essential Hypertension"],"enrollment":926,"completionDate":"2008-07"},{"nctId":"NCT00376181","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2006-06","conditions":["Type 2 Diabetes"],"enrollment":96,"completionDate":"2007-05"},{"nctId":"NCT00759551","phase":"PHASE2","title":"Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-08","conditions":["Hypertension"],"enrollment":555,"completionDate":"2005-06"}],"_emaApprovals":[{"date":"2011-12-07","status":"Authorised","company":"Takeda Pharma A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Edarbi"},{"form":"TABLET","route":"ORAL","productName":"Edarbyclor"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"180314","NDDF":"013661","UNII":"LL0G25K7I2","CHEBI":"CHEBI:68845","VANDF":"4030593","INN_ID":"8874","RXNORM":"1091642","UMLSCUI":"C2698291","chemblId":"CHEMBL2028661","ChEMBL_ID":"CHEMBL2028661","KEGG_DRUG":"D08067","DRUGBANK_ID":"DB08822","PUBCHEM_CID":"135409642","SNOMEDCT_US":"448917007","IUPHAR_LIGAND_ID":"6900","SECONDARY_CAS_RN":"863031-24-7","MESH_SUPPLEMENTAL_RECORD_UI":"C557413"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Arbor Pharmaceuticals","brandName":"Edarbi","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2011-","companyName":"Arbor Pharms Ireland","relationship":"Original Developer"},{"period":"2001","companyName":"Takeda Pharmaceutical Company Limited","relationship":"PMDA Licensee"},{"period":"2011","companyName":"Takeda Pharma A/S","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"11 hours"},"publicationCount":118,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C09CA09","allCodes":["C09CA09","C09DA09"]},"biosimilarFilings":[],"originalDeveloper":"Arbor Pharms Ireland","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Arbor Pharms Ireland","companyId":"arbor-pharms-ireland","modality":"Small molecule","firstApprovalDate":"2011","aiSummary":"","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"7572920","territory":"US","patent_type":null,"expiry_date":"2025-01-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7157584","territory":"US","patent_type":null,"expiry_date":"2025-05-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9066936","territory":"US","patent_type":null,"expiry_date":"2028-03-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9169238","territory":"US","patent_type":null,"expiry_date":"2030-02-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9387249","territory":"US","patent_type":null,"expiry_date":"2031-07-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T02:04:27.600761+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}